Successful treatment of granulomatous cheilitis with thalidomide

Archives of Dermatology

Volumn 139, Issue 2, 2003, Pages 136-138

  Thomas, Peter ^a   Walchner, Monika ^a   Ghoreschi, Kamran ^a   Röcken, Martin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; PREDNISONE; THALIDOMIDE;

ADULT; ARTICLE; CASE REPORT; CHEILITIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; FATIGUE; FEMALE; GRANULOMATOUS INFLAMMATION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIP BIOPSY; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; BIOPSY, NEEDLE; CHEILITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0037319999     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.2.136     Document Type: Article

References (25)

1. Biedermann T, Kneilling M, Mailhammer R, et al. Mast cells control neutrophil recruitment during T-cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med. 2000; 192:1441-1451.
2. Kaufman DR, Choi Y. Signaling by tumor necrosis factor receptors: pathways, paradigms and targets for therapeutic modulation. Int Rev Immunol. 1999;18: 405-427.
3. Allen CM, Camisa C, Hamzeh S, Stephens L. Cheilitis granulomatosa: report of six cases and review of the literature. J Am Acad Dermatol. 1990;23:444-450.
4. Hornstein O. Melkersson-Rosenthal syndrome: a challenge for dermatologists to participate in the field of oral medicine. J Dermatol. 1997;24:281-296.
5. Krutchkoff D, James R. Cheilitis granulomatosa: successful treatment with combined local triamcinolone injections and surgery. Arch Dermatol. 1978;114:1203-1206.
6. Podmore P, Burrows D. Clofazimine: an effective treatment for Melkersson-Rosenthal syndrome or Miescher's disease. Clin Exp Dermatol. 1986;11:173-178.
7. Tausch I, Sonnichsen N. Experiences with clofazimine therapy of Melkersson-Rosenthal syndrome. Hautarzt. 1992;43:194-198.
8. Stern RS. Systemic dapsone. Arch Dermatol. 1993;129:301-303.
9. Mellin GW, Katzenstein M. The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital abnormalities. N Engl J Med. 1962;23: 1184-1190.
10. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol. 1996;35:969-979.
11. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168:408-414.
12. Sheskin J. The treatment of lepra reaction in lepromatous leprosy: fifteen years experience with thalidomide. Int J Dermatol. 1980;19:318-322.
13. Carlesimo M, Giustina S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995; 32:866-869.
14. Sheskin J. Zur Therapie der Prurigo nodularis Hyde mit Thalidomid. Hautarzt. 1975;26:215-217.
15. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983;108:461-466.
16. Walchner M, Meurer M, Plewig G, Messer G. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol. 2000; 39:383-388.
17. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol. 1985;12:85-90.
18. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome [letter]. Arch Dermatol. 1982;118:536.
19. Rustin MH, Gilkes JH, Robinson TW. Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. J Am Acad Dermatol. 1990;23: 941-944.
20. Gutierrez Rodriguez O. Thalidomide: a promising new treatment for rheumatoid arthritis. Arthritis Rheum. 1984;27:1118-1121.
21. Vogelsang GB, Hess AD, Santos GW. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant. 1988;3:393-398.
22. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
23. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T-helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99:160-167.
24. Rowland TL, McHugh SM, Deighton J, Ewan PW, Dearman RJ. Kimber I. Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B. Int Immunopharmacol. 2001;1:49-61.
25. O'Dell JR. Anticytokine therapy: a new era in the treatment of rheumatoid arthritis? N Engl J Med. 1999;340:310-312.